日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer.

一项 I 期临床试验，研究肝动脉内递送 TG6002 与口服 5-氟胞胞嘧啶联合治疗以肝脏转移为主的结直肠癌患者的疗效

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-24-2498
West Emma J, Sadoun Alain, Bendjama Kaidre, Erbs Philippe, Smolenschi Cristina, Cassier Philippe A, de Baere Thierry, Sainte-Croix Sophie, Brandely Maud, Melcher Alan A, Ismail Fay, Scott Karen J, Bennett Angela, Banks Emma, Gasior Ewa, Kent Sarah, Kurzawa Marta, Hammond Christopher, Patel Jai V, Collinson Fiona J, Twelves Chris, Anthoney D Alan, Swinson Dan, Samson Adel
肿瘤
肠癌
发表日期：2025
文献求助 收藏

Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma

食管胃癌双重Erb B抑制剂（DEBIOC）：一项I期剂量递增安全性研究和随机剂量扩展研究，评估AZD8931联合奥沙利铂和卡培他滨化疗治疗食管胃腺癌患者的疗效

期刊:European Journal of Cancer
影响因子:7.1
doi:10.1016/j.ejca.2019.10.010
Thomas, Anne; Virdee, Pradeep S; Eatock, Martin; Lord, Simon R; Falk, Stephen; Anthoney, D Alan; Turkington, Richard C; Goff, Matthew; Elhussein, Leena; Collins, Linda; Love, Sharon; Moschandreas, Joanna; Middleton, Mark R
胃癌
肿瘤
肿瘤免疫
发表日期：2020
文献求助 收藏

Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses

TP300治疗晚期实体瘤患者的I期研究，包括药代动力学、药代遗传学和药效学分析

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/1471-2407-12-536
Anthoney, D Alan; Naik, Jay; Macpherson, Iain R J; Crawford, Donna; Hartley, John M; Hartley, Janet A; Saito, Tomohisa; Abe, Masaichi; Jones, Keith; Miwa, Masanori; Twelves, Christopher; Evans, T R J
P300
发表日期：2012
文献求助 收藏